The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Indirect treatment comparison of the efficacy of olaparib 300 mg tablets BID and cabazitaxel 25 mg/m2 every 3 weeks plus daily prednisolone and granulocyte colony-stimulating factor in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
 
Tim Reason
No Relationships to Disclose
 
Charles McCrea
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Robert Hettle
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Sameer Ghate
Employment - Merck Sharp & Dohme; Novartis
Stock and Other Ownership Interests - Advaxis (I); Bellicum Pharmaceuticals (I); Bellicum Pharmaceuticals (I); Calithera Biosciences (I); Idera (I); Mannkind; Provectus
 
Christian Heinrich Poehlein
Employment - Merck
Leadership - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
David Olmos
Honoraria - Astellas Pharma (Inst); Bayer; Janssen
Consulting or Advisory Role - AstraZeneca (Inst); Bayer; Bayer (Inst); Clovis Oncology; Daiichi Sankyo; Janssen; Janssen (Inst); MSD Oncology
Research Funding - Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca Spain; Bayer; Ipsen; Janssen; Roche